Literature DB >> 25869810

Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophrenia.

Marco Matos1, Hai-Ying Shen2, Elisabete Augusto1, Yumei Wang3, Catherine J Wei3, Yu Tian Wang4, Paula Agostinho5, Detlev Boison2, Rodrigo A Cunha5, Jiang-Fan Chen6.   

Abstract

BACKGROUND: Adenosine A2A receptors (A2AR) modulate dopamine and glutamate signaling and thereby may influence some of the psychomotor and cognitive processes associated with schizophrenia. Because astroglial A2AR regulate the availability of glutamate, we hypothesized that they might play an unprecedented role in some of the processes leading to the development of schizophrenia, which we investigated using a mouse line with a selective deletion of A2AR in astrocytes (Gfa2-A2AR knockout [KO] mice].
METHODS: We examined Gfa2-A2AR KO mice for behaviors thought to recapitulate some features of schizophrenia, namely enhanced MK-801 psychomotor response (positive symptoms) and decreased working memory (cognitive symptoms). In addition, we probed for neurochemical alterations in the glutamatergic circuitry, evaluating glutamate uptake and release and the levels of key proteins defining glutamatergic signaling (glutamate transporter-I [GLT-I], N-methyl-D-aspartate receptors [NMDA-R] and α-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors [AMPA-R]) to provide a mechanistic understanding of the phenotype encountered.
RESULTS: We show that Gfa2-A2AR KO mice exhibited enhanced MK-801 psychomotor response and decreased working memory; this was accompanied by a disruption of glutamate homeostasis characterized by aberrant GLT-I activity, increased presynaptic glutamate release, NMDA-R 2B subunit upregulation, and increased internalization of AMPA-R. Accordingly, selective GLT-I inhibition or blockade of GluR1/2 endocytosis prevented the psychomotor and cognitive phenotypes in Gfa2-A2AR KO mice, namely in the nucleus accumbens.
CONCLUSIONS: These results show that the dysfunction of astrocytic A2AR, by controlling GLT-I activity, triggers an astrocyte-to-neuron wave of communication resulting in disrupted glutamate homeostasis, thought to underlie several endophenotypes relevant to schizophrenia.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  A(2A)R; Adenosine; Astrocytes; GLT-I; NMDA-R; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 25869810      PMCID: PMC4714966          DOI: 10.1016/j.biopsych.2015.02.026

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  68 in total

Review 1.  Targeting glutamate synapses in schizophrenia.

Authors:  Julie R Field; Adam G Walker; P Jeffrey Conn
Journal:  Trends Mol Med       Date:  2011-09-28       Impact factor: 11.951

2.  Expression of equilibrative nucleoside transporter type 1 protein in elderly patients with schizophrenia.

Authors:  Dan Shan; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Neuroreport       Date:  2012-03-07       Impact factor: 1.837

Review 3.  Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior.

Authors:  Michael M Halassa; Philip G Haydon
Journal:  Annu Rev Physiol       Date:  2010       Impact factor: 19.318

4.  A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization.

Authors:  Elena Bastia; Yue-Hang Xu; Angela C Scibelli; Yuan-Ji Day; Joel Linden; Jiang-Fan Chen; Michael A Schwarzschild
Journal:  Neuropsychopharmacology       Date:  2005-05       Impact factor: 7.853

5.  Nucleus accumbens long-term depression and the expression of behavioral sensitization.

Authors:  Karen Brebner; Tak Pan Wong; Lidong Liu; Yitao Liu; Paul Campsall; Sarah Gray; Lindsay Phelps; Anthony G Phillips; Yu Tian Wang
Journal:  Science       Date:  2005-11-25       Impact factor: 47.728

Review 6.  Working memory and long-term memory deficits in schizophrenia: is there a common substrate?

Authors:  Jared Xavier Van Snellenberg
Journal:  Psychiatry Res       Date:  2009-10-17       Impact factor: 3.222

7.  A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs.

Authors:  Hai-Ying Shen; Joana E Coelho; Nobuhisa Ohtsuka; Paula M Canas; Yuan-Ji Day; Qing-Yuan Huang; Nelson Rebola; Liqun Yu; Detlev Boison; Rodrigo A Cunha; Joel Linden; Joe Z Tsien; Jiang-Fan Chen
Journal:  J Neurosci       Date:  2008-03-19       Impact factor: 6.167

8.  Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms.

Authors:  Liqun Yu; Hai-Ying Shen; Joana E Coelho; Inês M Araújo; Qing-Yuan Huang; Yuan-Ji Day; Nelson Rebola; Paula M Canas; Erica Kirsten Rapp; Jarrod Ferrara; Darcie Taylor; Christa E Müller; Joel Linden; Rodrigo A Cunha; Jiang-Fan Chen
Journal:  Ann Neurol       Date:  2008-03       Impact factor: 10.422

Review 9.  The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia.

Authors:  Charles B Mikell; Guy M McKhann; Solomon Segal; Robert A McGovern; Matthew B Wallenstein; Holly Moore
Journal:  Stereotact Funct Neurosurg       Date:  2009-06-26       Impact factor: 1.875

10.  Regulated delivery of AMPA receptor subunits to the presynaptic membrane.

Authors:  Ursula Schenk; Claudia Verderio; Fabio Benfenati; Michela Matteoli
Journal:  EMBO J       Date:  2003-02-03       Impact factor: 11.598

View more
  47 in total

1.  Antipsychotic-Like Efficacy of Dopamine D2 Receptor-Biased Ligands is Dependent on Adenosine A2A Receptor Expression.

Authors:  Kristoffer Sahlholm; Maricel Gómez-Soler; Marta Valle-León; Marc López-Cano; Jaume J Taura; Francisco Ciruela; Víctor Fernández-Dueñas
Journal:  Mol Neurobiol       Date:  2017-08-05       Impact factor: 5.590

Review 2.  Comorbidities in Neurology: Is adenosine the common link?

Authors:  Detlev Boison; Eleonora Aronica
Journal:  Neuropharmacology       Date:  2015-05-13       Impact factor: 5.250

3.  Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.

Authors:  K Xu; D G Di Luca; M Orrú; Y Xu; J-F Chen; M A Schwarzschild
Journal:  Neuroscience       Date:  2016-02-22       Impact factor: 3.590

4.  Astrocytic A2A receptors: Novel targets to manage brain disorders: PS168.

Authors:  Vanessa Henriques; Nélio Gonçalves; Paula Agostinho; Rodrigo A Cunha
Journal:  Porto Biomed J       Date:  2017-09-01

Review 5.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 6.  Purinergic system in psychiatric diseases.

Authors:  A Cheffer; A R G Castillo; J Corrêa-Velloso; M C B Gonçalves; Y Naaldijk; I C Nascimento; G Burnstock; H Ulrich
Journal:  Mol Psychiatry       Date:  2017-09-26       Impact factor: 15.992

7.  Adenosine Kinase Expression in the Frontal Cortex in Schizophrenia.

Authors:  Cassidy L Moody; Adam J Funk; Emily Devine; Ryan C Devore Homan; Detlev Boison; Robert E McCullumsmith; Sinead M O'Donovan
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

Review 8.  Physiology of Astroglia.

Authors:  Alexei Verkhratsky; Maiken Nedergaard
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

9.  Developmental role of adenosine kinase for the expression of sex-dependent neuropsychiatric behavior.

Authors:  D M Osborne; U S Sandau; A T Jones; J W Vander Velden; A M Weingarten; N Etesami; Y Huo; H Y Shen; D Boison
Journal:  Neuropharmacology       Date:  2018-08-23       Impact factor: 5.250

10.  Adenosine A2A receptor and ecto-5'-nucleotidase/CD73 are upregulated in hippocampal astrocytes of human patients with mesial temporal lobe epilepsy (MTLE).

Authors:  Aurora R Barros-Barbosa; Fátima Ferreirinha; Ângela Oliveira; Marina Mendes; M Graça Lobo; Agostinho Santos; Rui Rangel; Julie Pelletier; Jean Sévigny; J Miguel Cordeiro; Paulo Correia-de-Sá
Journal:  Purinergic Signal       Date:  2016-09-20       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.